SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 239,240.89 |
| Enterprise Value ($M) | 263,168.89 |
| Book Value ($M) | 44,560.00 |
| Book Value / Share | 17.64 |
| Price / Book | 5.37 |
| NCAV ($M) | -31,952.00 |
| NCAV / Share | -12.65 |
| Price / NCAV | -7.49 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.21 |
| Return on Assets (ROA) | 0.16 |
| Return on Equity (ROE) | 0.41 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.15 |
| Current Ratio | 1.36 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 38,782.00 |
| Assets | 117,106.00 |
| Liabilities | 70,734.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 64,168.00 |
| Operating Income | 24,031.00 |
| Net Income | 17,117.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 21,468.00 |
| Cash from Investing | -7,734.00 |
| Cash from Financing | -7,032.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 10.02 | 3.47 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,175,311 | 8,790,939 | 13.37 | |
| 1,598,069 | 13,335,268 | 11.98 | |
| 1,371,612 | 9,207,772 | 14.90 | |
| 1,407,857 | 11,256,126 | 12.51 | |
| 1,324,704 | 12,535,594 | 10.57 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| HYAC – Haymaker Acquisition Corp. 4 | JNJ – Johnson & Johnson |
| LLY – Eli Lilly and Company | NUVB – Nuvation Bio Inc. |
| OGN – Organon & Co. |